Anemia and chronic heart failure implications and treatment options - PubMed (original) (raw)

Review

. 2008 Aug 12;52(7):501-11.

doi: 10.1016/j.jacc.2008.04.044.

Affiliations

• PMID: 18687241
• DOI: 10.1016/j.jacc.2008.04.044

Free article

Review

Anemia and chronic heart failure implications and treatment options

Inder S Anand. J Am Coll Cardiol. 2008.

Free article

Abstract

Anemia is a common comorbidity in patients with heart failure and is associated with worse long-term outcomes. Although the cause of anemia in heart failure is unclear, the weight of evidence suggests that renal dysfunction, along with neurohormonal and proinflammatory cytokine activation in heart failure, favors the development of anemia of chronic disease, with defective iron utilization, inappropriate erythropoietin production, and depressed bone marrow function. Similarly, the mechanisms by which anemia worsens heart failure outcomes are unknown but may be related to increased myocardial workload. If anemia is a mediator and not just a marker of poor outcomes, correcting anemia could become an important and novel therapeutic target to improve long-term outcomes in such patients. Indeed, several small-sized studies have shown the beneficial effects of empirically treating anemia in heart failure patients with recombinant erythropoietin and intravenous iron. However, the ideal threshold at which therapy should be initiated and the extent of correction considered safe and desirable in the individual patient with heart failure need to be known. These issues become more important because of increasing safety concerns that recombinant erythropoietin therapy for treating anemia may be associated with adverse cardiovascular outcomes in patients with chronic kidney disease and may worsen cancer in patients receiving chemotherapy to treat various types of cancer. Therefore, further prospectively designed studies are required to address some of these questions. Fortunately, 2 large mortality morbidity trials, TREAT (Trial to Reduce Cardiovascular Events with Aranesp Therapy) in patients with chronic kidney disease and RED-HF (Reduction of Events with Darbepoetin alfa in Heart Failure) in heart failure patients, are in progress and are likely to provide definitive answers.

PubMed Disclaimer

Similar articles

• The interaction between heart failure and other heart diseases, renal failure, and anemia.
  Silverberg DS, Wexler D, Iaina A, Schwartz D. Silverberg DS, et al. Semin Nephrol. 2006 Jul;26(4):296-306. doi: 10.1016/j.semnephrol.2006.05.006. Semin Nephrol. 2006. PMID: 16949468 Review.
• Mechanisms of Disease: erythropoietin resistance in patients with both heart and kidney failure.
  van der Putten K, Braam B, Jie KE, Gaillard CA. van der Putten K, et al. Nat Clin Pract Nephrol. 2008 Jan;4(1):47-57. doi: 10.1038/ncpneph0655. Nat Clin Pract Nephrol. 2008. PMID: 18094727 Review.
• The role of anemia in the progression of congestive heart failure. Is there a place for erythropoietin and intravenous iron?
  Silverberg DS, Wexler D, Iaina A. Silverberg DS, et al. J Nephrol. 2004 Nov-Dec;17(6):749-61. J Nephrol. 2004. PMID: 15593047 Review.
• Pathogenesis of anemia in cardiorenal disease.
  Anand IS. Anand IS. Rev Cardiovasc Med. 2005;6 Suppl 3:S13-21. Rev Cardiovasc Med. 2005. PMID: 16340934 Review.
• Therapy insight: congestive heart failure, chronic kidney disease and anemia, the cardio-renal-anemia syndrome.
  Iaina A, Silverberg DS, Wexler D. Iaina A, et al. Nat Clin Pract Cardiovasc Med. 2005 Feb;2(2):95-100. doi: 10.1038/ncpcardio0094. Nat Clin Pract Cardiovasc Med. 2005. PMID: 16265380 Review.

Cited by

• Association between low selenoprotein P concentrations and anaemia in hospitalized heart failure patients.
  Jujić A, Molvin J, Holm Isholth H, Dieden A, Korduner J, Zaghi A, Nezami Z, Bergmann A, Schomburg L, Magnusson M. Jujić A, et al. ESC Heart Fail. 2024 Apr;11(2):877-882. doi: 10.1002/ehf2.14651. Epub 2024 Jan 10. ESC Heart Fail. 2024. PMID: 38200550 Free PMC article.
• [Heart failure and anemia].
  Reda S, Motloch LJ, Hoppe UC. Reda S, et al. Herz. 2013 Sep;38(6):597-603. doi: 10.1007/s00059-013-3901-4. Herz. 2013. PMID: 23900390 German.
• T cell and monocyte/macrophage activation markers associate with adverse outcome, but give limited prognostic value in anemic patients with heart failure: results from RED-HF.
  Abraityte A, Aukrust P, Kou L, Anand IS, Young J, Mcmurray JJV, van Veldhuisen DJ, Gullestad L, Ueland T. Abraityte A, et al. Clin Res Cardiol. 2019 Feb;108(2):133-141. doi: 10.1007/s00392-018-1331-2. Epub 2018 Jul 26. Clin Res Cardiol. 2019. PMID: 30051179 Clinical Trial.
• Improving prognosis estimation in patients with heart failure and the cardiorenal syndrome.
  Abdel-Qadir HM, Chugh S, Lee DS. Abdel-Qadir HM, et al. Int J Nephrol. 2011;2011:351672. doi: 10.4061/2011/351672. Epub 2011 May 18. Int J Nephrol. 2011. PMID: 21660113 Free PMC article.
• Long-term outcomes in patients with Takotsubo syndrome.
  Imamura T. Imamura T. Int J Cardiol Heart Vasc. 2021 Mar 4;35:100744. doi: 10.1016/j.ijcha.2021.100744. eCollection 2021 Aug. Int J Cardiol Heart Vasc. 2021. PMID: 34458556 Free PMC article. No abstract available.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • ClinicalKey
  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal